Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel

Summary Patients receiving dual antiplatelet treatment with aspirin and clopidogrel are commonly treated with proton pump inhibitors (PPIs). Attenuating effects on platelet response to clopidogrel have been reported solely for the PPI omeprazole. PPIs differ in their metabolisation properties as well as their potential for drug-drug interactions. The aim of this study was to investigate the impact of different PPIs (pantoprazole, omeprazole, esomeprazole) on platelet response to clopidogrel in patients with previous coronary stent placement under chronic clopidogrel treatment. In a cross-sectional observational study, consecutive patients under clopidogrel maintenance treatment (n=1,000) scheduled for a control coronary angiography were enrolled. Adenosine diphosphate (ADP)-induced platelet aggregation (in AU*min) was measured with multiple electrode platelet aggregometry (MEA). From the entire study population, 268 (26.8%) patients were under PPI treatment at the time point of platelet function testing (pantoprazole, n=162; omeprazole, n=64; esomeprazole, n=42). Platelet aggregation (median [interquar-tile range]) was significantly higher in patients with omeprazole treatment (295.5 [193.5–571.2] AU*min) compared to patients without PPI treatment (220.0 [143.8–388.8] AU*min; p=0.001). Platelet aggregation was similar in patients with pantoprazole (226.0 [150.0–401.5] AU*min) or esomeprazole (209.0 [134.8–384.8] AU*min) treatment compared to patients without PPI treatment (p=0.69 and p=0.88, respectively). Attenuating effects of concomitant PPI treatment on platelet response to clopidogrel were restricted to the use of omeprazole. No attenuating effects on platelet response to clopidogrel were observed for pantoprazole or esomeprazole. Specifically designed and randomized clinical studies are needed to define the impact of concomitant PPI treatment on adverse events after percutaneous coronary intervention.

[1]  Adnan Kastrati,et al.  Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. , 2009, Journal of the American College of Cardiology.

[2]  E. Antman,et al.  ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use , 2008, The American Journal of Gastroenterology.

[3]  R. Epstein,et al.  Abstract 3998: Proton Pump Inhibitors Effect on Clopidogrel Effectiveness: The Clopidogrel Medco Outcomes Study , 2008 .

[4]  S. Steinhubl,et al.  Abstract 3999: Baseline Proton Pump Inhibitor Use is Associated with Increased Cardiovascular Events With and Without the Use of Clopidogrel in the CREDO Trial , 2008 .

[5]  J. Rumsfeld,et al.  Abstract 6241: Proton Pump Inhibitors May Attenuate the Benefits of Clopidogrel among ACS Patients: Empirical Evidence from 3,311 ACS Patients , 2008 .

[6]  A. Gadisseur,et al.  Multiplate whole blood impedance aggregometry: A recent experience , 2008, Thrombosis and Haemostasis.

[7]  S. Shi,et al.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics , 2008, European Journal of Clinical Pharmacology.

[8]  T. Arafat,et al.  Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel , 2008, Journal of clinical pharmacy and therapeutics.

[9]  J. Badimón,et al.  Clinical implications of clopidogrel resistance , 2008, Thrombosis and Haemostasis.

[10]  J. Badimón,et al.  Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease , 2008, Thrombosis and Haemostasis.

[11]  A. Kastrati,et al.  Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. , 2008, European heart journal.

[12]  M. Fromm,et al.  Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. , 2008, Journal of the American College of Cardiology.

[13]  Andrew J. Johnson,et al.  Multiple electrode aggregometry and P2Y12 antagonists , 2008, Thrombosis and Haemostasis.

[14]  K. Winters,et al.  Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel , 2008, Journal of clinical pharmacology.

[15]  Dominique Mottier,et al.  Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. , 2008, Journal of the American College of Cardiology.

[16]  A. Kastrati,et al.  Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment , 2007, Thrombosis and Haemostasis.

[17]  S. Iturria,et al.  Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel , 2007, Journal of thrombosis and haemostasis : JTH.

[18]  S. Steinhubl,et al.  Platelet function monitoring in patients with coronary artery disease. , 2007, Journal of the American College of Cardiology.

[19]  M. Gawaz,et al.  The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score , 2007, Journal of thrombosis and haemostasis : JTH.

[20]  C. Macaya,et al.  Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. , 2007, Journal of the American College of Cardiology.

[21]  A. Kastrati,et al.  Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. , 2007, The American journal of cardiology.

[22]  A. Gori,et al.  Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. , 2007, Journal of the American College of Cardiology.

[23]  C. Macaya,et al.  Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. , 2007, Journal of the American College of Cardiology.

[24]  P. Gurbel,et al.  Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? , 2007, Journal of the American College of Cardiology.

[25]  W. Siess,et al.  Glycoprotein Ibα inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques , 2007, Thrombosis and Haemostasis.

[26]  W. Siess,et al.  Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood , 2006, Thrombosis and Haemostasis.

[27]  F. Neumann,et al.  Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. , 2006, Journal of the American College of Cardiology.

[28]  A. Bura,et al.  Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. , 2006, Blood.

[29]  J. Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Circulation.

[30]  C. Macaya,et al.  Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. , 2005, Diabetes.

[31]  U. Hofmann,et al.  Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. , 2005, Clinical pharmacology and therapeutics.

[32]  Deepak L. Bhatt,et al.  Variability in platelet responsiveness to clopidogrel among 544 individuals. , 2005, Journal of the American College of Cardiology.

[33]  Marie M. Ahlström,et al.  Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[34]  P. Watkins,et al.  Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance , 2004, Circulation.

[35]  David Julius,et al.  Identification of the platelet ADP receptor targeted by antithrombotic drugs , 2001, Nature.

[36]  J. Herbert,et al.  Identification and Biological Activity of the Active Metabolite of Clopidogrel , 2000, Thrombosis and Haemostasis.

[37]  C. Stedman,et al.  Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors , 2000, Alimentary pharmacology & therapeutics.

[38]  M. Ua.  Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. , 1996 .

[39]  K. Devault,et al.  ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use , 2011 .

[40]  B. Jilma,et al.  Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. , 2009, American heart journal.

[41]  H. Blume,et al.  Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors , 2006, Drug safety.

[42]  Joseph P Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Journal of the American College of Cardiology.

[43]  U. Meyer,et al.  Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. , 1996, The Yale journal of biology and medicine.